Abstract
Cardiotoxicity represents the main drawback of clinical usefulness of anthracycline antineoplastic drugs. In this study, a content of selected elements (Ca, Mg, K, Se, Fe) in the post-mortem removed samples of the myocardial tissue was studied in three groups of rabbits: 1) control group (i.v. saline; n = 10); 2) daunorubicin-receiving animals (DAU; 3 mg/kg, i.v; n=11); 3) animals receiving cardioprotective iron-chelating agent dexrazoxane (DEX; 60 mg/kg, i.p.; n=5) prior to DAU. Drugs were administered once weekly for 10 weeks. 5–7 days after the last administration, cardiac left ventricular contractility (dP/dtmax) was significantly decreased in DAU-treated animals (745 ± 69 versus 1245 ± 86 kPa/s in the control group; P < 0.05), while in the DEX+DAU group it was insignificantly increased (1411 ± 77 kPa/s). Of the myocardial elements’ content studied, a significant increase in total Ca against control (16.2 ± 2.4 versus 10.6 ± 0.9 μg/g of dry tissue; P < 0.05) was determined in the DAU-group, which was accompanied with significant decreases in Mg and K. In the heart tissue of DEX-pretreated animals, no significant changes of elements’ content were found as compared to controls, while the Ca content was in these animals significantly lower than in the DAU group (9.1 ± 0.4 versus 16.2 ± 2.4 μg/g; P < 0.05). Hence, in this study we show that systolic heart failure induced by chronic DAU administration is primarily accompanied by persistent calcium overload of cardiac tissue and the protective action of DEX is associated with the restoration of normal myocardial Ca content.
Similar content being viewed by others
References
M Adamcova V Pelouch V Gersl J Kaplanova Y Mazurova T Simunek I Klimtova R. Hrdina (2003) ArticleTitleProtein profiling in daunorubicin-induced cardiomyopathy Gen Physiol Biophys 22 411–419
KP Burton AC Morris KD Massey LM Buja HK Hagler (1990) ArticleTitleFree radicals alter ionic calcium levels and membrane phospholipids in cultured rat ventricular myocytes J Mol Cell Cardiol 22 1035–1047
JL Buss BB Hasinoff (1993) ArticleTitleThe one-ring open hydrolysis product intermediates of the cardioprotective agent ICRF-187 (dexrazoxane) displace iron from iron-anthracycline complexes Agents Actions 40 86–95
P Calabresi BA. Chabner (2001) Chemotherapy of neoplastic diseases JG Hardman LE Limbird (Eds) Goodman & Gilman’s The pharmacological basis of therapeutics EditionNumber10 McGraw-Hill New York 1381–1459
WH Cheng YS Ho BA Valentine DA Ross GF Combs SuffixJr XG Lei (1998) ArticleTitleCellular glutathione peroxidase is the mediator of body selenium to protect against paraquat lethality in transgenic mice J Nutr 128 1070–1076
M Chiesi G. Inesi (1981) ArticleTitleMg 2+and Mn 2+ modulation of Ca2+ transport and ATPase activity in sarcoplasmic reticulum vesicles Arch Biochem Biophys 208 586–592
P. Delva (2003) ArticleTitleMagnesium and heart failure Mol Aspects Med 24 79–105
JH. Doroshow (1983) ArticleTitleAnthracycline antibiotic-stimulated superoxide, hydrogen peroxide, and hydroxyl radical production by NADH dehydrogenase Cancer Res 43 543–551
V Geršl R. Hrdina (1994) ArticleTitleNoninvasive polygraphic cardiac changes in daunorubicin-induced cardiomyopathy in rabbits Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove 37 49–55
L Gille H. Nohl (1997) ArticleTitleAnalyses of the molecular mechanism of adriamycin-induced cardiotoxicity Free Radic Biol Med 23 775–782
I Halili-Rutman C Hershko G Link AJ Rutman A. Shainberg (1997) ArticleTitleInhibition of calcium accumulation by the sarcoplasmic reticulum: a putative mechanism for the cardiotoxicity of adriamycin Biochem Pharmacol 54 211–214
MC Haigney S Wei S Kaab E Griffiths R Berger R Tunin D Kass WG Fisher B Silver H. Silverman (1998) ArticleTitleLoss of cardiac magnesium in experimental heart failure prolongs and destabilizes repolarization in dogs J Am Coll Cardiol 31 701–706
BB Hasinoff K Hellmann EH Herman VJ. Ferrans (1998) ArticleTitleChemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines Curr Med Chem 5 1–28
EH Herman VJ. Ferrans (1998) ArticleTitlePreclinical animal models of cardiac protection from anthracycline-induced cardiotoxicity Semin Oncol 25 15–21
SR Holmberg DV Cumming Y Kusama DJ Hearse PA Poole-Wilson MJ Shattock AJ. Williams (1991) ArticleTitleReactive oxygen species modify the structure and function of the cardiac sarcoplasmic reticulum calcium-release channel Cardioscience 2 19–25
SR Holmberg AJ. Williams (1990) ArticleTitlePatterns of interaction between anthraquinone drugs and the calcium-release channel from cardiac sarcoplasmic reticulum Circ Res 67 272–283
M Horie H Irisawa A. Noma (1987) ArticleTitleVoltage-dependent magnesium block of adenosine-triphosphate-sensitive potassium channel in guinea-pig ventricular cells J Physiol 387 251–272
R Hrdina V Gersl I Klimtova T Simunek J Machackova M. Adamcova (2000) ArticleTitleAnthracycline-induced cardiotoxicity Acta Medica (Hradec Kralove) 43 75–82 Occurrence Handle1:CAS:528:DC%2BD3cXnvV2lu7Y%3D
AR Imondi P Della Torre G Mazue TM Sullivan TL Robbins LM Hagerman A Podesta G Pinciroli (1996) ArticleTitleDose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs Cancer Res 56 4200–4204
K Ishihara T Mitsuiye A Noma M. Takano (1989) ArticleTitleThe Mg2+ block and intrinsic gating underlying inward rectification of the K+ current in guinea-pig cardiac myocytes J Physiol 419 297–320
I Klimtová T Simunek Y Mazurova R Hrdina V Gersl M. Adamcova (2002) ArticleTitleComparative study of chronic toxic effects of daunorubicin and doxorubicin in rabbits Hum Exp Toxicol 21 649–657
JC Kwok DR. Richardson (2000) ArticleTitleThe cardioprotective effect of the iron chelator dexrazoxane (ICRF-187) on anthracycline-mediated cardiotoxicity Redox Rep 5 317–324 Occurrence Handle10.1179/135100000101535898 Occurrence Handle1:CAS:528:DC%2BD3MXjvVSrug%3D%3D Occurrence Handle11140743
JC Kwok DR. Richardson (2003) ArticleTitleAnthracyclines induce accumulation of iron in ferritin in myocardial and neoplastic cells: inhibition of the ferritin iron mobilization pathway Mol Pharmacol 63 849–861
G Minotti P Menna E Salvatorelli G Cairo L. Gianni (2004) ArticleTitleAnthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity Pharmacol Rev 56 185–229
RD Olson PS. Mushlin (1990) ArticleTitleDoxorubicin cardiotoxicity: analysis of prevailing hypotheses FASEB J 4 3076–3086 Occurrence Handle1:CAS:528:DyaK3MXhs12ktA%3D%3D Occurrence Handle2210154
IN Pessah EL Durie MJ Schiedt I. Zimanyi (1990) ArticleTitleAnthraquinone-sensitized Ca 2+ release channel from rat cardiac sarcoplasmic reticulum: possible receptor-mediated mechanism of doxorubicin cardiomyopathy Mol Pharmacol 37 503–514
S Rajagopalan PM Politi BK Sinha CE. Myers (1988) ArticleTitleAdriamycin-induced free radical formation in the perfused rat heart: implications for cardiotoxicity Cancer Res 48 4766–4769
MA Ralston MR Murnane RE Kelley RA Altschuld DV Unverferth CV. Leier (1989) ArticleTitleMagnesium content of serum, circulating mononuclear cells, skeletal muscle, and myocardium in congestive heart failure Circulation 80 573–580
DR. Richardson (1997) ArticleTitlePotential of iron chelators as effective antiproliferative agents Can J Physiol Pharmacol 75 1164–1180
A Romani A. Scarpa (1992) ArticleTitleRegulation of cell magnesium Arch Biochem Biophys 298 1–12
NE Saris E Mervaala H Karppanen JA Khawaja A. Lewenstam (2000) ArticleTitleMagnesium An update on physiological, clinical and analytical aspects Clin Chim Acta 294 1–26
S Sartori I Nielsen D Tassinari A Maestri V. Abbasciano (1991) ArticleTitleIntracellular magnesium concentrations and acute anthracycline-induced cardiotoxicity Br J Cancer 64 785–787
KJ Schimmel DJ Richel RB Brink Particlevan den HJ Guchelaar (2004) ArticleTitleCardiotoxicity of cytotoxic drugs Cancer Treat Rev 30 181–191 Occurrence Handle10.1016/j.ctrv.2003.07.003
K Shan AM Lincoff JB. Young (1996) ArticleTitleAnthracycline-induced cardiotoxicity Ann Intern Med 125 47–58 Occurrence Handle1:STN:280:BymB2crgvVU%3D Occurrence Handle8644988
SM Swain P. Vici (2004) ArticleTitleThe current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review J Cancer Res Clin Oncol 130 1–7
TF Tam R Leung-Toung W Li Y Wang K Karimian M. Spino (2003) ArticleTitleIron chelator research: past, present, and future Curr Med Chem 10 983–995
K Temma A Chugun T Akera Y Hara T Sasaki H. Kondo (1997) ArticleTitleCa 2+ overloading causes the negative inotropic effect of doxorubicin in myocytes isolated from guinea-pig hearts Eur J Pharmacol 322 235–242
LR Wiseman CM. Spencer (1988) ArticleTitleDexrazoxane A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy Drugs 56 385–403
X Yin H Wu Y Chen YJ. Kang (1998) ArticleTitleInduction of antioxidants by adriamycin in mouse heart Biochem Pharmacol 56 87–93
Author information
Authors and Affiliations
Corresponding author
Additional information
Published online: March 2005
Rights and permissions
About this article
Cite this article
Šimůnek, T., Štěrba, M., Holečková, M. et al. Myocardial content of selected elements in experimental anthracycline-induced cardiomyopathy in rabbits. Biometals 18, 163–169 (2005). https://doi.org/10.1007/s10534-004-4491-7
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10534-004-4491-7